Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents

27 Aug 2012

Abstract excerpt

DNA-damaging agents (DDAs) constitute the backbone of treatment for most human tumors. Here we used the National Cancer Institute Antitumor Cell Line Panel (the NCI-60) to identify predictors of cancer cell response to topoisomerase I (Top1) inhibitors, a widely used class of DDAs. We assessed the NCI-60 transcriptome using Affymetrix Human Exon 1.0 ST microarrays and correlated the in vitro activity of four Top1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22927417
DOI: 10.1073/pnas.1205943109

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agentsPMID 22927417Read ↗

SLFN11 is a general target for enhancing the sensitivity of cancer to chemotherapy (DNA-damaging agents)Semantic proximity Read ↗

SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidanceSemantic proximity Read ↗

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in ovarian cancerSemantic proximity Read ↗

Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapySemantic proximity Read ↗

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugsSemantic proximity Read ↗

The crucial role of single-stranded DNA binding in enhancing sensitivity to DNA-damaging agents for Schlafen 11 and Schlafen 13Semantic proximity Read ↗

Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity.Semantic proximity Read ↗

Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replicationSemantic proximity Read ↗

Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in CancerSemantic proximity Read ↗

SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitorsSemantic proximity Read ↗

The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoningSemantic proximity Read ↗

Cracking the Code: Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.